Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case–control study of older men and women

Summary.  Background: CD40 ligand(CD40L) is implicated in atherosclerotic plaque formation. Objectives: We investigated prospective associations between circulating soluble CD40L and myocardial infraction (MI) or stroke in an older general population cohort, accounting for established and novel cardiovascular risk factors. Methods: Baseline serum CD40L (sCD40L) was measured in incident MI (n = 368) and stroke (n = 304) cases and two controls per case, ‘nested’ in prospective UK studies of 4252 men and 4286 women aged 60–79 years, sampled from general practices in Britain in 1998–2000, with 7‐year follow‐up for fatal and non‐fatal MI and stroke. Results:  sCD40L was higher in smokers and negatively associated with lung function and positively associated with total cholesterol and markers of inflammation, but not with other established cardiovascular disease (CVD) risk factors. Geometric mean sCD40L levels did not differ between MI cases and controls (5.94 ng mL−1 vs. 5.82 ng mL−1; P = 0.5) or between stroke cases and controls (5.61 ng mL−1 vs. 5.28 ng mL−1, P = 0.1). There was no strong evidence for elevated risk of MI or stroke in multivariable models comparing participants in the top to those in the bottom third of sCD40L. Age‐adjusted odds ratios (ORs) were 1.39 [95% confidence interval (CI) 0.98, 1.96] for MI and 1.16 (0.78, 1.73) for stroke. These attenuated to 1.24 (95% CI 0.86, 1.79) and 1.18 (0.78, 1.78), respectively, after adjustment for established and novel CVD risk factors. Conclusions:  sCD40L is associated with other inflammatory markers but is not itself a strong independent risk marker for either stroke or MI.

[1]  C. Stefanadis,et al.  The CD40/CD40 ligand system: linking inflammation with atherothrombosis. , 2009, Journal of the American College of Cardiology.

[2]  J. Mair,et al.  Lack of association of soluble CD40 ligand with the presence of acute myocardial infarction or ischemic stroke in the emergency department. , 2009, Clinical chemistry.

[3]  M. Woodward,et al.  Associations of plasma pro‐inflammatory cytokines, fibrinogen, viscosity and C‐reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study , 2008, British journal of haematology.

[4]  Nader Rifai,et al.  Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. , 2008, European heart journal.

[5]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[6]  V. Fuster,et al.  Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  C. Stefanadis,et al.  Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes , 2007, European journal of clinical investigation.

[8]  H. Katus,et al.  Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. , 2007, Clinical chemistry.

[9]  G. Lip,et al.  High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis , 2007, Stroke.

[10]  P. Libby,et al.  Influence of pre-analytical and analytical factors on soluble CD40L measurements. , 2006, Clinical science.

[11]  A. Siegbahn,et al.  Soluble CD40L Levels Are Regulated by the −3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[12]  C. Heeschen,et al.  Influence of sample type and storage conditions on soluble CD40 ligand assessment. , 2006, Clinical chemistry.

[13]  E. Lonn,et al.  The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. , 2005, Atherosclerosis.

[14]  P. Libby,et al.  Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Whincup,et al.  The British Regional Heart Study 1975-2004. , 2004, International journal of epidemiology.

[16]  Jian Zhu,et al.  The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[17]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[18]  Peter H. Whincup,et al.  Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[19]  L. Horstman,et al.  Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. , 2004, Thrombosis research.

[20]  S. Verma,et al.  Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II , 2003, Circulation.

[21]  S. Verma,et al.  New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.

[22]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[23]  W. Daniel,et al.  Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia , 2003, Stroke.

[24]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, New England Journal of Medicine.

[25]  D. Lawlor,et al.  Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study , 2003, Journal of epidemiology and community health.

[26]  F. Lampe,et al.  Non-attendance at re-examination 20 years after screening in the British Regional Heart Study. , 2002, Journal of public health medicine.

[27]  P. Whincup,et al.  Physical Activity and Hemostatic and Inflammatory Variables in Elderly Men , 2002, Circulation.

[28]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[29]  J. Danesh,et al.  Fibrin D-Dimer and Coronary Heart Disease: Prospective Study and Meta-Analysis , 2001, Circulation.

[30]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[31]  T. Pietrucha,et al.  Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. , 1996, Thrombosis research.

[32]  B Rosner,et al.  Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. , 1992, American journal of epidemiology.

[33]  HYPERTENSION and coronary heart disease: classification and criteria for epidemiological studies. , 1959, World Health Organization technical report series.